SCM
TRIB

Stonepine Capital Management’s Trinity Biotech TRIB Stock Holding History

Stonepine Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-24,534
Closed -$688K – 30
2017
Q3 		$688K Sell
24,534
-37,865
-61% -$1.06M 0.41% 20
2017
Q2 		$1.87M Sell
62,399
-7,984
-11% -$226K 1.01% 21
2017
Q1 		$2.1M Sell
70,383
-16,830
-19% -$526K 1.18% 17
2016
Q4 		$3.02M Buy
+87,213
New +$3M 1.8% 17

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Stonepine Capital Management's TRIB Position: Q4 2017 in Review

Stonepine Capital Management sold out of Trinity Biotech (TRIB) in Q4 2017, closing a stake of 24,534 shares — an estimated $688K sold.

Stonepine Capital Management first reported a position in TRIB in Q4 2016 and held it in 4 quarters. The position peaked at $3.02M in Q4 2016. 48 funds tracked by Wall St. Rank hold TRIB as of Q4 2017.

  • Stonepine Capital Management reported no remaining Trinity Biotech position as of Q4 2017 after selling out during the quarter.
  • Stonepine Capital Management sold 24,534 Trinity Biotech shares in Q4 2017, an estimated $688K.
  • Stonepine Capital Management first reported a position in Trinity Biotech in Q4 2016 and held it in 4 quarters.
  • Stonepine Capital Management's Trinity Biotech position peaked at $3.02M in Q4 2016.
  • 48 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2017.

Based on Stonepine Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.